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ABSTRACT 
 
Background: Obstructive sleep apnea (OSA) is common in patients with coronary artery disease 
(CAD). Earlier research has not investigated whether CAD patients should be screened for OSA and 
subsequently treated with continuous positive airway pressure (CPAP) even if they have no 
symptoms. This thesis investigated the prevalence and predictors of OSA in a newly revascularized 
CAD cohort, and further addressed the relationship between OSA and diastolic dysfunction among 
patients with left ventricular ejection fraction (LVEF) ≥50%. Moreover, the impact of CPAP 
treatment on diastolic function as well as on long-term cardiovascular outcomes was evaluated in 
patients with CAD and non-sleepy OSA.  
 
Methods: Patients who underwent a mechanical revascularization in Skaraborg, Sweden, between 
September 2005 and November 2010 (n=1,291) were invited to participate. Anthropometrics and 
medical history were obtained, ambulatory sleep recording was performed, and all subjects 
completed the Epworth Sleepiness Scale (ESS) questionnaire. OSA diagnosis was based on an 
apnea–hypopnea index (AHI) ≥15/h, and no OSA was defined as an AHI <5/h. Left atrial diameter, 
myocardial relaxation velocity (é), and the ratio of early diastolic mitral flow to myocardial 
relaxation velocity (E/é (were evaluated as echocardiographic diastolic function parameters at 
baseline, three months, and one year. The long-term primary endpoint was the first event of new 
revascularization, myocardial infarction, stroke or cardiovascular death. Intention-to-treat (ITT) and 
on-treatment analyses were performed for evaluation of the impact of CPAP in the randomized 
controlled arm of the CAD patients with non-sleepy OSA (ESS score <10).  
 
Results: OSA was found among 422 of the 662 study participants (64%), of whom 62% were non-
sleepy. The prevalence of OSA was higher than the prevalence of obesity, hypertension, diabetes, 
and current smoking. In the subgroup of patients with preserved LVEF, worse diastolic function was 
more common in the OSA group (54% vs 41%, p=0.019). OSA was significantly associated with 
worse diastolic function after adjustment for confounding factors. Regarding the impact of CPAP 
treatment, there was no significant improvement in any of the diastolic function parameters in non-
sleepy OSA patients in the ITT analysis. Neither were long-term adverse outcomes reduced 
significantly in the ITT population (n=244) during a median follow-up of 57 months. In the on-
treatment analysis, CPAP usage of at least four hours per night was associated with an  increase in é 
tissue velocity after adjustment for the confounding factors (odds ratio 2.3, 95% confidence interval 
(CI) 1.0–4.9; p=0.039). This level of CPAP usage was associated also with a risk reduction (hazard 
ratio 0.29; 95% CI 0.10–0.86; p=0.026) in long-term adverse outcomes after adjustment for the 
baseline comorbidities.  
 
Conclusions: The prevalence of unrecognized OSA in this CAD cohort was higher than previously 
reported, and OSA was associated with worse diastolic function among patients with preserved 
LVEF. Routine prescription of CPAP to CAD patients with non-sleepy OSA had no beneficial 
impact on diastolic function and long-term outcomes in the ITT population. However, there was a 
significant risk reduction after adjustment for baseline comorbidities and CPAP adherence. These 
findings need to be further explored in larger clinical cohorts with more homogeneous CAD 
populations.  
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